Home Cart Sign in  
Chemical Structure| 1020172-07-9 Chemical Structure| 1020172-07-9

Structure of Rebastinib
CAS No.: 1020172-07-9

Chemical Structure| 1020172-07-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1 (WT) and Abl1 (T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2.

Synonyms: DCC-2036

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rebastinib

CAS No. :1020172-07-9
Formula : C30H28FN7O3
M.W : 553.59
SMILES Code : O=C(NC)C1=NC=CC(OC2=CC=C(NC(NC3=CC(C(C)(C)C)=NN3C4=CC=C5N=CC=CC5=C4)=O)C(F)=C2)=C1
Synonyms :
DCC-2036
MDL No. :MFCD19443646
InChI Key :WVXNSAVVKYZVOE-UHFFFAOYSA-N
Pubchem ID :25066467

Safety of Rebastinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Rebastinib

RTK

Isoform Comparison

Biological Activity

Target
  • Abl

    u-Abl1 (T315I), IC50:5 nM

    p-Abl1 (native), IC50:0.75 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HUVECs 0.058 nM Inhibition of Ang1-stimulated Tie2 kinase activity Mol Cancer Ther. 2017 Nov;16(11):2486-2501.
EA.hy926 0.091 nM Inhibition of Ang1-stimulated Tie2 kinase activity Mol Cancer Ther. 2017 Nov;16(11):2486-2501.
iBMM Tie2Hi 0.26 nM Inhibition of Tie2 phosphorylation Mol Cancer Ther. 2017 Nov;16(11):2486-2501.
CHO 2.0 nM Inhibition of Tie2 activity Mol Cancer Ther. 2017 Nov;16(11):2486-2501.
HBMVECs 1 μM Rebastinib inhibited CCM3 loss-induced EC sprouting and lumen formation Nat Commun. 2021 Jan 25;12(1):504.
HEK 293 cells 0.5 μM 4 h Rebastinib does not hinder ligand-induced stimulation of ErbB1, ErbB2, and ErbB4 in HEK 293 cells. Invest Ophthalmol Vis Sci. 2023 Jul 3;64(10):6.
HBMVECs 1 μM Rebastinib inhibited the increased EC sprouting and lumen formation induced by CCM3 knockdown, restoring normal vascular structure. Nat Commun. 2021 Jan 25;12(1):504.
TIE-2+ M-MDSC 5 nM Rebastinib effectively restored the IFN-γ production by tumor-specific T cells inactivated by ANGPT2 exposition. Front Immunol. 2022 Jul 22;13:932298.
HeLa cells 10 μM Evaluated the selectivity of Rebastinib on kinases in HeLa cells, finding that 86% of kinases were efficiently competed Mol Cell. 2023 Mar 2;83(5):803-818.e8.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Breast cancer model Oral 10 mg/kg Twice per week for 4 weeks Rebastinib inhibits TMEM doorway function, reducing TMEM Activity-MRI NPJ Breast Cancer. 2022 Sep 2;8(1):101
Mouse Pdcd10BECKO mouse model Subcutaneous injection 10 μg/g Daily injection from P4 to P14, then weekly injection from P15 to P60 Rebastinib significantly reduced the number and size of CCM lesions and restored EC-pericyte interactions Nat Commun. 2021 Jan 25;12(1):504.
Mice Pdcd10BECKO mouse model Subcutaneous injection 10 μg/g Daily from P4 to P14, or daily from P8 to P18, and weekly from P19 to P60 Rebastinib significantly reduced the number and size of CCM lesions, restored EC-pericyte interactions, and improved vascular integrity. Nat Commun. 2021 Jan 25;12(1):504.
Mouse MMTV-PyMT mouse mammary tumor model Oral 10 mg/kg Daily for 4 weeks Inhibition of tumor growth, metastasis, and extension of survival Mol Cancer Ther. 2017 Nov;16(11):2486-2501.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00827138 Chronic Myeloid Leukemia PHASE1 COMPLETED 2025-01-13 City of Hope, Duarte, Californ... More >>ia, 91010, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|Emory University, Atlanta, Georgia, 30322, United States|University of Chicago, Chicago, Illinois, 60637, United States|The University of Kansas Cancer Center, Kansas City, Kansas, 66160, United States|Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, 21287, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.81mL

0.36mL

0.18mL

9.03mL

1.81mL

0.90mL

18.06mL

3.61mL

1.81mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories